Endometrial cancer

Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer

Retrieved on: 
Montag, Juni 3, 2024
Șaeș, ASCO, RECIST, Lung, CDK2, Vomiting, Fatigue, Endometrial cancer, Patient, Diarrhea, Annual general meeting, NSCLC, Safety, Society, Pharmacokinetics, Pancreatic cancer, Cyclacel, CDKN2B, PD, CDK9, T-cell lymphoma, CDKN2A, Lymphoma, CYCC, Poster, Hyperglycemia, Nausea, Pharmaceutical industry

BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as oral monotherapy was presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL. See link to poster here.

Key Points: 
  • “We are excited to report data with fadraciclib monotherapy from the entire Phase 1 population at ASCO.
  • Clinical benefit was observed in heavily pretreated patients with several tumor types, including endometrial, lung, ovarian, pancreatic cancer, and T-cell lymphoma,” said Spiro Rombotis, President and Chief Executive officer.
  • In addition, clinical benefit was reported in two patients with endometrial cancer, and one each with ovarian and pancreatic cancers.
  • The proof of concept part of the study is now enrolling patients with CDKN2A/B loss or T-cell lymphoma.

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO® Annual Meeting

Retrieved on: 
Donnerstag, Mai 30, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Relapse, Follicular lymphoma, Paclitaxel, Finish line, Drug development, Metastatic breast cancer, Breast cancer, Tumor microenvironment, Sarah Cannon Research Institute, Breast, Lead, Master, Consolidation, HealthOne, Durvalumab, Meta-analysis, CDT, OU Health, Total cost, PD-L1, Survival, Clinical trial, Quality, MPH, Endometrial cancer, NSCLC, SCRI, ASCO, Safety, BCMA, Society, Cetuximab, Doctor of Philosophy, Efficacy, Spacecraft, Metastasis, Monoclonal antibody, Acute myeloid leukemia, Abstract, HCA Healthcare, Role, Annual general meeting, Birth control

“We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.

Key Points: 
  • “We look forward to connecting with colleagues from around the world at ASCO’s Annual Meeting to discuss the latest developments in advancing therapies for cancer patients,” says Howard A.
  • To learn more about our research experts, visit our Leadership Page .
  • “Clinical Trial Participation and End-of-Life Care Among Older Adults: A Multi-Center Longitudinal Observational Cohort Analysis of 121,717 Patients with Cancer,” Dr.
  • “Performance of Comprehensive Genomic Profiling versus Single Gene Testing in Guideline-Recommended Biomarker Selection in Non-Small Cell Lung Cancer,” Dr. V. Subbiah, 1:30 p.m. - 4:30 p.m. CDT, Hall A.

Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

Retrieved on: 
Donnerstag, Mai 23, 2024
MSD, Pembrolizumab, Merck & Co., Patient, Oxidative stress, TPS, Trastuzumab, Science, HER2, Proteostasis, Tumor microenvironment, FDA, Endometrial cancer, Safety, Breast cancer, ADC, Senior, Headquarters, LEAP, Research, Deep, Cancer, Drug discovery, ASCO, Merck, PRISM, Society, Apoptosis, Hepatocellular carcinoma, Differentiable function, Inflammation, Hypoxia, Annual general meeting, Pharmaceutical industry

TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.

Key Points: 
  • TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains with the aim of contributing to the cure of cancers.
  • (1) KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Retrieved on: 
Donnerstag, Mai 23, 2024
Patient, Pharmacokinetics, Gynecologic Oncology (journal), Female, Ovarian cancer, Toxicity, Ovary, Docetaxel, Cmax, Recurrence, Endometrial cancer, Safety, Disease, Wayne State University, AUC, RECIST, Senior, Triple-negative breast cancer, Part, Cancer, Melanoma, Incidence, ASCO, PDC, Associate, FACOG, Neoplasm, Society, Aes, Therapy, TNBC, TSX, Pharmaceutical industry

The poster presentation, which constitutes the first report of long-term efficacy, safety, and pharmacokinetic (PK) data from the Phase 1 study, also suggests that sudocetaxel zendusortide has a manageable safety profile when dosed at 300mg/m2, with few Grade 3 adverse events (AEs).

Key Points: 
  • The poster presentation, which constitutes the first report of long-term efficacy, safety, and pharmacokinetic (PK) data from the Phase 1 study, also suggests that sudocetaxel zendusortide has a manageable safety profile when dosed at 300mg/m2, with few Grade 3 adverse events (AEs).
  • “It is highly unusual to see such long-lasting disease stabilization even after treatment cessation in patients with advanced disease.
  • Sudocetaxel zendusortide has a manageable safety profile, with most treatment-related AEs rated as mild to moderate in severity and managed with standard supportive care or dose reductions.
  • The maximum concentration (Cmax) of sudocetaxel zendusortide was 30.4 micromolar (μM), compared to 0.58 μM for free docetaxel.

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

Retrieved on: 
Donnerstag, Mai 23, 2024
Clinical research, Patient, Pharmacokinetics, Juan Carlos Ferrero, Interleukin, VISTA, FDA, Sensei, Endometrial cancer, Safety, PD-1, Cancer, TMDD, ASCO, CRC, Kinetics, Poster, Society, Aes, Therapy, Immunotherapy, Webcast, NEXT, Antibody, MSS, CRS, Tumor necrosis factor, Pharmaceutical industry

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

Key Points: 
  • There is a continued unmet need for patient populations that have become resistant or don’t respond to current immunotherapy treatment options.
  • I look forward to continuing to evaluate its progress.”
    The dose escalation portion of the Phase 1/2 clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101.
  • These clinical data are consistent with preclinical studies suggesting therapeutically relevant clinical doses of SNS-101 at 3mg/kg or higher.
  • Dr. Sen is an investigator on the ongoing Phase 1/2 clinical trial for SNS-101, and lead author of the SNS-101 poster.

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

Retrieved on: 
Montag, Mai 20, 2024
Patient, Fulvestrant, Hope, Gynecologic Oncology (journal), Ovarian cancer, Panagiotis Konstantinopoulos, Translational research, Therapy, Endometrial cancer, Malignancy, Enzyme inhibitor, Cancer, Harvard Medical School, Letrozole, Division, Associate, IST, DFCI, Breast, Phase II, Female, Pharmaceutical industry

“Endometrial cancer is the most prevalent cancer affecting the female reproductive organs in the United States,” said Dr. Konstantinopoulos.

Key Points: 
  • “Endometrial cancer is the most prevalent cancer affecting the female reproductive organs in the United States,” said Dr. Konstantinopoulos.
  • “While early detection offers hope for successful treatment, patients with recurrent or metastatic disease have limited treatment options.
  • Similarly, low grade serous ovarian cancer has shown sensitivity to combined treatment with aromatase inhibitors and CDK4/6 inhibition, but responding patients eventually develop disease progression.
  • This trial represents a significant step forward in our collective efforts to address the complexities of endometrial cancer and low grade serous ovarian cancer.

Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO® Annual Meeting

Retrieved on: 
Freitag, Mai 24, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, ERBB2, Patient, Lung, Doctor of Philosophy, Cancer, DNA, Booth, AKT1, MBC, PBO, HER2, Circulating tumor DNA, Prevalence, PIK3CA, Endometrial cancer, TALA, Neoplasm, MD, Abstract, CGP, ASCO, Foundation Medicine, Talazoparib, RNA, Society, PTEN, Breast, Annual general meeting, Medical imaging

Foundation Medicine, Inc ., today announced that 22 new pieces of research from its robust oncology diagnostics portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago.

Key Points: 
  • Foundation Medicine, Inc ., today announced that 22 new pieces of research from its robust oncology diagnostics portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago.
  • “We are also excited to demonstrate our new RNA sequencing capabilities and spotlight the expanding utility of ctDNA to inform treatment decision making through a simple blood sample.”
    The following is a complete list of Foundation Medicine abstracts that will be presented.
  • To access the abstracts being presented at ASCO, please visit ASCO.org/abstracts .
  • Follow Foundation Medicine on LinkedIn , X and Instagram for more updates from #ASCO24 and visit us in person at Booth #22031.

Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting

Retrieved on: 
Donnerstag, Mai 23, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Patient, Renal cell carcinoma, Nimbus, Therapy, Update, Syngenic, Endometrial cancer, Safety, Pancreatic cancer, ASCO, HPK1, B cell, Society, Combination therapy, Annual general meeting, RCC, Pharmaceutical industry

Results are being highlighted in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.

Key Points: 
  • Results are being highlighted in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.
  • The Phase 1/2 multicenter, open-label trial is designed to assess NDI-101150 as a monotherapy (50-200 mg dose) and in combination with 200 mg pembrolizumab in the treatment of adults with advanced solid tumors.
  • The results being presented at the ASCO Annual Meeting include updated data from 44 patients in the dose escalation cohorts (n=38 on monotherapy, n=6 on combination therapy) and additional data from 15 patients in the dose expansion cohorts.
  • Results, as of March 18, 2024, showed:
    Treatment with NDI-101150 monotherapy was associated with clinical benefit in five out of 30 (16.7%) response-evaluable patients.

Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline

Retrieved on: 
Mittwoch, Mai 15, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, HER2, BTC, Cisplatin, PBC, Brentuximab vedotin, HCC, INT, Merck & Co., Pros, Endometrial cancer, ADC, Abstract, Melanoma, Hepatocellular carcinoma, Physician, PD-L1, Quality of life (healthcare), TNBC, Pembrolizumab, Safety, NSCLC, Cancer, Carcinoma, ASCO, Society, Patient, AHCC, Lung cancer, Therapy, Radiation, Daiichi Sankyo, MRK, Conjugation, Webcast, Quality of life, Annual general meeting, Georgetown University, Pharmaceutical industry

New data being shared at the meeting showcase the company’s continued progress to advance clinical research for Merck’s broad portfolio and diverse pipeline of investigational candidates.

Key Points: 
  • New data being shared at the meeting showcase the company’s continued progress to advance clinical research for Merck’s broad portfolio and diverse pipeline of investigational candidates.
  • “This year’s ASCO is also particularly meaningful as we approach 10 years since KEYTRUDA was first approved in the U.S.
  • As Merck continues to build its broad oncology portfolio, the company will also present data at ASCO from its diverse pipeline of investigational candidates, many being evaluated in combination with KEYTRUDA.
  • Merck will hold an Oncology Investor Event to coincide with the 2024 ASCO Annual Meeting on Monday, June 3, 2024, 6 p.m. CT, at which senior management will provide an update on the company’s oncology strategy and program.

Caris Life Sciences to Showcase Extensive Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at ASCO 2024

Retrieved on: 
Dienstag, Mai 14, 2024
SCLC, Lung, Patient, Prognosis, Doctor of Philosophy, Immunotherapy, POA, PIWIL1, Diagnosis, Neoplasm, Endometrial cancer, TP53, Carcinoma, Breast cancer, NSCLC, Prostate, MBA, MD, Prostate cancer, Abstract, Research, Cancer, Biomarker, ASCO, CRC, Data analysis, Lung cancer, Medicine, ESR1, RNA, Society, Hepatocellular carcinoma, Genotype, Breast, NCI, HSD3B1, Annual general meeting, Medical imaging

IRVING, Texas, May 14, 2024 /PRNewswire/ -- Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from the biopharma industry and leading cancer centers, including those within the Caris Precision Oncology Alliance™ (POA), will collectively present 41 studies across 19 tumor types at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting May 31 to June 4, 2024 (Booth #28001). The findings demonstrate the power of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • Through extensive sequencing and data analysis efforts, we're unlocking new avenues for tailored therapies to revolutionize cancer treatment."
  • (Abstract Number: 8088)
    Poster and abstract summaries highlighting the Caris research presented at ASCO 2024 will be available onsite at Caris' Booth 28001.
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.
  • POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.